Document Detail


Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease?
MedLine Citation:
PMID:  11151417     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clonidine, a centrally active alpha 2-adrenoreceptor agonist used to lower blood pressure, has been proposed to differentiate central from peripheral autonomic deficits and multiple system atrophy (MSA) from untreated idiopathic Parkinson's disease (IPD). A lack of growth hormone (GH) increase after clonidine infusion is found in patients with MSA, but not in those with IPD or with pure autonomic failure. We studied 19 IPD and 7 MSA patients to assess whether this test could be used in clinical practice to distinguish MSA from IPD, whatever the stage of the disease. Serum GH levels were measured 15, 30, 45 and 60 min after a 10-min infusion of 2 micrograms/kg clonidine. GH levels remained stable after clonidine infusion in all 7 MSA patients but increased in only 12 of the 19 IPD patients, while remaining stable in the other 7. No correlation was found with the presence of orthostatic hypotension. We conclude that the GH response to clonidine infusion has a very high sensitivity (100% in our series and in previous studies) for the diagnosis of MSA. However, this response cannot be used as a diagnostic test because of its poor specificity.
Authors:
C Tranchant; C Guiraud-Chaumeil; A Echaniz-Laguna; J M Warter
Related Documents :
779587 - The use of clonidine and practolol in the treatment of hypertension.
8485447 - Oral clonidine premedication prevents the rise in intraocular pressure following succin...
3426347 - Involvement of cholinergic mechanisms in the central cardiovascular actions of nicardip...
578267 - Withdrawal of antihypertensive therapy. hypertensive crisis in renovascular hypertension.
1237877 - Influences of chronic denervation of the carotid bifurcation regions on panting in the ...
12413257 - Perioperative plasma concentrations of atrial and brain natriuretic peptides in patient...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of neurology     Volume:  247     ISSN:  0340-5354     ISO Abbreviation:  J. Neurol.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2001-01-09     Completed Date:  2001-04-05     Revised Date:  2004-12-15    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  853-6     Citation Subset:  IM    
Affiliation:
Service des Maladies du Système Nerveux et du Muscle, Hôpitaux Universitaires, 1 Place de l'Hôpital, 67091 Strasbourg, France. christine tranchant@chru-strasbourg.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Clonidine / diagnostic use*
Diagnosis, Differential
Female
Growth Hormone / drug effects*
Humans
Male
Middle Aged
Multiple System Atrophy / diagnosis*
Parkinson Disease / diagnosis*
Chemical
Reg. No./Substance:
4205-90-7/Clonidine; 9002-72-6/Growth Hormone
Comments/Corrections
Comment In:
J Neurol. 2002 Apr;249(4):488-9   [PMID:  11967661 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Geographical distribution of amyotrophic lateral sclerosis with neurofibrillary tangles in the Kii P...
Next Document:  Botulinum toxin for treatment of craniofacial hyperhidrosis.